NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street

NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street

The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.

Ashley Mastronardi delivers the pre-market update on October 8th

  • Stocks are fractionally higher Wednesday as traders await minutes from the Federal Reserve's latest meeting. The gains come after the S&P 500 snapped a seven-day winning streak.
  • The Federal Reserve meeting minutes should provide clues this afternoon on the path forward for interest rates, while investors keep their focus on long-term opportunities.
  • Fanatics Advertising will present the Advertising Week Playmaker Awards at the NYSE this evening. They spotlight innovators in sports that are rewriting the rules of engagement.

Opening Bell
Empire State Realty Trust (NYSE: ESRT) celebrates the 47th Annual Empire State Building Run-Up – Presented by NYU Langone Health

Closing Bell
Nuvation Bio (NYSE: NUVB) celebrates the approval of its first medicine in June and transforming into a commercial-stage company with a promising pipeline

Click here to download the NYSE TV App

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nyse-content-advisory-pre-market-update--the-aw-playmaker-awards-take-the-stage-at-11-wall-street-302578344.html

SOURCE New York Stock Exchange

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2025/08/c1492.html

News Provided by Canada Newswire via QuoteMedia

NUVB
The Conversation (0)
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors. "We are delighted to have Dr. Mashal... Keep Reading...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by... Keep Reading...
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash equivalents, and marketable securities... Keep Reading...
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formation of oncology-focused... Keep Reading...
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...
Satellos Bioscience Inc.

Satellos Bioscience Inc.

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this... Keep Reading...
Vaxcyte Inc.

Vaxcyte Inc.

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. Keep Reading...

Interactive Chart

Latest Press Releases

Related News